Abvc BiopharmaABVC
13F holders, Q1 2025 (March 31)10holders −3
0new positions
3sold out
$1.06avg. 13F price*
At the end of Q1 2025, 10 institutions reported holding Abvc Biopharma Inc. (ABVC) in their 13F filings, down 3 from Q4 2024. 0 opened new positions and 3 sold out. The largest holders were Geode Capital Management, LLC ($111K), XTX Topco Ltd ($64K) and Vanguard Group Inc. ($50K).
- Company
- Abvc Biopharma Inc.
- CUSIP
- 00091F304
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $118K |
All 13F filers, Q4 2024 → Q1 2025: 80,241 shares bought and 201,971 shares sold, net −121,730 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Geode Capital Management, LLC | 0.00% | Add +31.8% | 104,482 | $111K |
| XTX Topco Ltd | 0.00% | Add +75.7% | 60,439 | $64K |
| Vanguard Group Inc. | 0.00% | No change | 46,947 | $50K |
| UBS Group AG | 0.00% | Add +289930.0% | 29,003 | $31K |
| Northern Trust Corp. | 0.00% | No change | 19,135 | $20K |
| State Street Corp. | 0.00% | No change | 12,900 | $14K |
| Two Sigma Securities, LLC | 0.00% | Reduce -8.9% | 11,470 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +0.5% | 2,576 | $3K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -30.5% | 460 | $488 |
| Bank of America Corp. | 0.00% | Add +4.9% | 85 | $90 |
"% of holder's portfolio" is ABVC's weight in each manager's 13F, not the share of Abvc Biopharma Inc. the manager owns.